Ling Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ling Xu has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Fan Yang
Thyroid and Breast Surgery Peking University First Hospital Beijing China
4 shared publicationsHong-Jin Liu
Breast Disease Center, Peking University First Hospital, Beijing, China
4 shared publicationsLing Xin
Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China
4 shared publications- Ming-Shuai Sun
Breast Disease Center, Peking University First Hospital, Beijing, China
4 shared publications Qian Liu
Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China
4 shared publications- Qian Wu
Department of Thyroid and Breast Surgery Peking University First Hospital Beijing China
4 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 162-168
Clinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2− Breast Cancer: From Subtyping to Chemotherapy De-escalation
- 24 August 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (10) , 162-168
Open AccessClinical Validation of the MammaTyper LRP Model for Identification of Low-Risk Patients With Early-Stage ER+/HER2− Breast Cancer: From Subtyping to Chemotherapy De-escalation
- Open Access
- 11 October 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (5)
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report
The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) in patients with breast cancer is often delayed, and this condition is associated with high mortality. A 71‐year‐old female with CR‐MAHA secondary to bone marrow metastasis received trastuzumab deruxtecan (T‐DXd) after first‐line chemotherapy failure and achieved partial hematological remission. Treatment was discontinued because of interstitial lung disease (ILD). Early antitumor therapy is crucial; antibody‐drug conjugates such as T‐DXd offer promise, but vigilance for adverse effects is needed.
- 11 October 2025
- Published by Wiley in Cancer Innovation
- Vol. 4 (5)
Open AccessTrastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report
The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) in patients with breast cancer is often delayed, and this condition is associated with high mortality. A 71‐year‐old female with CR‐MAHA secondary to bone marrow metastasis received trastuzumab deruxtecan (T‐DXd) after first‐line chemotherapy failure and achieved partial hematological remission. Treatment was discontinued because of interstitial lung disease (ILD). Early antitumor therapy is crucial; antibody‐drug conjugates such as T‐DXd offer promise, but vigilance for adverse effects is needed.
- Open Access
- 2 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions
Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positive breast cancer brain metastasis (BCBM) patients and their prognostic associations, to identify personalized treatment strategies to enhance survival. This retrospective study included HER2-positive BCBM patients treated at three institutions: the Fifth Medical Center of the Chinese PLA General Hospital, Peking University First Hospital, and the First Affiliated Hospital of Xi’an Jiaotong University. Clinical, pathological, and treatment data were collected. A prognostic model was developed using recursive variable selection, starting with significant variables from univariate analysis and refining them through a recursive loop in multivariate Cox regression. The model stratified patients into three risk groups: low-risk (score 0–1), intermediate-risk (score 2–3), and high-risk (score 4–6), based on various independent prognostic factors. The median survival times for the low-, intermediate-, and high-risk groups were 30, 20, and 10 months, respectively (P < 0.0001, HR1 = 1.35, 95% CI: 0.94–1.94; HR2 = 4.02, 95% CI: 2.4–6.73). The mean ROC curve AUC values for the 1-year, 2-year, and 3-year prognostic predictions were 0.69, 0.70, and 0.61, respectively. In the independent validation cohort of 75 patients, prognostic stratification into low-, intermediate-, and high-risk groups revealed significant differences in outcomes (73 months vs. 35 months vs. 9 months, P < 0.001, HR1 = 2.68, 95% CI: 1.30–5.52; HR2 = 8.82, 95% CI: 3.89–19.97). The mean AUC value for the 1-year and 2-year prognostic predictions in the validation cohort was 0.94, whereas the mean AUC value for the 3-year prognostic prediction was 0.81. This study developed a prognostic stratification model for HER2-positive BCBM patients based on clinicopathological characteristics.
- 2 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessDevelopment of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions
Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positive breast cancer brain metastasis (BCBM) patients and their prognostic associations, to identify personalized treatment strategies to enhance survival. This retrospective study included HER2-positive BCBM patients treated at three institutions: the Fifth Medical Center of the Chinese PLA General Hospital, Peking University First Hospital, and the First Affiliated Hospital of Xi’an Jiaotong University. Clinical, pathological, and treatment data were collected. A prognostic model was developed using recursive variable selection, starting with significant variables from univariate analysis and refining them through a recursive loop in multivariate Cox regression. The model stratified patients into three risk groups: low-risk (score 0–1), intermediate-risk (score 2–3), and high-risk (score 4–6), based on various independent prognostic factors. The median survival times for the low-, intermediate-, and high-risk groups were 30, 20, and 10 months, respectively (P < 0.0001, HR1 = 1.35, 95% CI: 0.94–1.94; HR2 = 4.02, 95% CI: 2.4–6.73). The mean ROC curve AUC values for the 1-year, 2-year, and 3-year prognostic predictions were 0.69, 0.70, and 0.61, respectively. In the independent validation cohort of 75 patients, prognostic stratification into low-, intermediate-, and high-risk groups revealed significant differences in outcomes (73 months vs. 35 months vs. 9 months, P < 0.001, HR1 = 2.68, 95% CI: 1.30–5.52; HR2 = 8.82, 95% CI: 3.89–19.97). The mean AUC value for the 1-year and 2-year prognostic predictions in the validation cohort was 0.94, whereas the mean AUC value for the 3-year prognostic prediction was 0.81. This study developed a prognostic stratification model for HER2-positive BCBM patients based on clinicopathological characteristics.
- 8 May 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4525-4538
HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer
Purpose Human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with 18F-FDG PET/CT. Methods In this prospective study conducted from May 2024 to Jan 2025, participants with newly diagnosed breast cancer underwent both 68Ga-HER2-affibody and 18F-FDG PET/CT examinations. The relationship between PET parameters (such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor-to-background SUV ratio (TBR)) and HER2 expression statuses (HER2-zero, -low and -positive) was analyzed. Results A total of 57 female participants (58 primary lesions) with newly diagnosed breast cancer were included. In the paired comparison of 68Ga-HER2-affibody and 18F-FDG PET/CT, HER2-TBR was higher than FDG-TBR in the HER2-low and HER2-positive group, respectively (P < 0.001). HER2-SUVmax and HER2-SUVmean exhibited differences across most comparisons, especially HER2-zero vs. -low (P < 0.05). HER2-SUVmean emerged as an independent predictor (P = 0.01; OR: 2.8) for differentiating HER2-low/positive and -zero, yielding an AUC of 0.91. Under detailed HER2 immunohistochemistry, HER2-SUVmax, -SUVmean and -TBR demonstrated intergroup differences (P < 0.05). Conclusion HER2-targeted PET/CT imaging demonstrated distinct advantages over 18F-FDG PET/CT imaging in characterizing the HER2 status of primary lesions. Parameters based on HER2-affibody differed significantly among different HER2 statuses, and might be potential imaging indicators for screening patients with HER2-low/positive who could benefit from HER2-targeted ADCs. ClinicalTrials.gov identifier NCT06289517 (2024-03-04).
- 8 May 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4525-4538
HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer
Purpose Human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with 18F-FDG PET/CT. Methods In this prospective study conducted from May 2024 to Jan 2025, participants with newly diagnosed breast cancer underwent both 68Ga-HER2-affibody and 18F-FDG PET/CT examinations. The relationship between PET parameters (such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor-to-background SUV ratio (TBR)) and HER2 expression statuses (HER2-zero, -low and -positive) was analyzed. Results A total of 57 female participants (58 primary lesions) with newly diagnosed breast cancer were included. In the paired comparison of 68Ga-HER2-affibody and 18F-FDG PET/CT, HER2-TBR was higher than FDG-TBR in the HER2-low and HER2-positive group, respectively (P < 0.001). HER2-SUVmax and HER2-SUVmean exhibited differences across most comparisons, especially HER2-zero vs. -low (P < 0.05). HER2-SUVmean emerged as an independent predictor (P = 0.01; OR: 2.8) for differentiating HER2-low/positive and -zero, yielding an AUC of 0.91. Under detailed HER2 immunohistochemistry, HER2-SUVmax, -SUVmean and -TBR demonstrated intergroup differences (P < 0.05). Conclusion HER2-targeted PET/CT imaging demonstrated distinct advantages over 18F-FDG PET/CT imaging in characterizing the HER2 status of primary lesions. Parameters based on HER2-affibody differed significantly among different HER2 statuses, and might be potential imaging indicators for screening patients with HER2-low/positive who could benefit from HER2-targeted ADCs. ClinicalTrials.gov identifier NCT06289517 (2024-03-04).
- 6 May 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4511-4524
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT
Purpose The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs. Methods Consecutive 207 breast cancer patients (211 primary lesions), who underwent 18F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed. Results TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (P < 0.05). TLR (P = 0.03; OR: 1.1) and Nottingham grade (P = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC testing set = 0.86). Conclusion Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.
- 6 May 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (12) , 4511-4524
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using 18F-FDG PET/CT
Purpose The intricateness of tumor immune microenvironment types (TIMTs) complicates identifying responders to immune checkpoint inhibitors (ICIs). Our purpose was to explore the metabolic characteristics of TIMTs in breast cancer using 18F-fluorodeoxyglucose (FDG) PET/CT and to establish radiomics-based predictive models for TIMTs. Methods Consecutive 207 breast cancer patients (211 primary lesions), who underwent 18F-FDG PET/CT examination from Sep 2022 to Aug 2024 in our hospital, were retrospectively reviewed. The programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) were evaluated for TIMTs: TMIT-I (PD-L1-, TILs-), TMIT-II (PD-L1+, TILs+), TMIT-III (PD-L1-, TILs+), and TMIT-IV (PD-L1+, TILs-). The relationship between metabolic parameters (such as maximum standardized uptake value (SUVmax) and tumor-to-liver SUV ratio (TLR)) and TIMTs was analyzed. Then composite predictive models based on radiomics were further developed. Results TIMT-II represented the highest proportion in HER2+ (14/22, 64%) and triple-negative (17/27, 63%) breast cancer. Most metabolic parameters (such as SUVmax and TLR) exhibited significant differences in TIMT-II vs. -I or TIMT-II vs. -III (P < 0.05). TLR (P = 0.03; OR: 1.1) and Nottingham grade (P = 0.006; OR: 3.1) were independent impact factors of TIMT-II. We further developed a composite model that integrated radiomics, metabolic parameter, and clinicopathological data, which demonstrated promising predictive efficacy for TIMT-II (AUC testing set = 0.86). Conclusion Metabolic differences existed among different TIMTs, with TIMT-II exhibiting markedly elevated metabolic characteristics. The composite model based on radiomics demonstrated high predictive efficacy for TIMT-II and has the potential to screen ICIs responders.
- 17 December 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (7) , 2769-2777
Axillary lymph node management strategies in cN + breast cancer patients after neoadjuvant chemotherapy
With the widespread use of neoadjuvant chemotherapy (NAC), the optimal management strategy for axillary lymph nodes following chemotherapy has become a hot topic of discussion. For patients with clinically positive axillary lymph nodes (cN +) (defined as axillary lymph nodes confirmed positive by pathology before NAC), axillary lymph node dissection (ALND) remains the current standard treatment. However, there is still no consensus on whether sentinel lymph node biopsy (SLNB) and other local axillary treatments following NAC can safely replace ALND to reduce injury and complications. This article provides a narrative review of strategies for managing axillary lymph nodes in this patient population.
- 17 December 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (7) , 2769-2777
Axillary lymph node management strategies in cN + breast cancer patients after neoadjuvant chemotherapy
With the widespread use of neoadjuvant chemotherapy (NAC), the optimal management strategy for axillary lymph nodes following chemotherapy has become a hot topic of discussion. For patients with clinically positive axillary lymph nodes (cN +) (defined as axillary lymph nodes confirmed positive by pathology before NAC), axillary lymph node dissection (ALND) remains the current standard treatment. However, there is still no consensus on whether sentinel lymph node biopsy (SLNB) and other local axillary treatments following NAC can safely replace ALND to reduce injury and complications. This article provides a narrative review of strategies for managing axillary lymph nodes in this patient population.
- Open Access
- 22 June 2024
- Published by Elsevier in The Breast
- Vol. 76, 103762
The features of male breast cancer in China: A real-world study
- 22 June 2024
- Published by Elsevier in The Breast
- Vol. 76, 103762
Open AccessThe features of male breast cancer in China: A real-world study
- Open Access
- 8 June 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (6) , 1-11
Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis
Purpose: The biomarker characteristics of breast cancer plays an important role in predicting treatment sensitivity. The aim of the present study was to compare immunohistochemical profiles (ER, PR, HER2, and Ki67) between the primary tumor and synchronous axillary lymph node metastasis and investigate the subsequent effects on neoadjuvant therapy response. Methods: A total of 358 patients with pathologically confirmed synchronous axillary lymph node metastasis at first diagnosis and treated by neoadjuvant therapy at Peking University First Hospital from January 1, 2013 to December 31, 2022 were included in this retrospective study. Clinicopathologic data, especially receptor status in primary and metastatic foci, was collected for each case. Results: Change of ER, PR, HER2, and Ki67 expression was observed in 5.9%, 8.7%, 12.6%, and 17.3% of patients, respectively. HR discordance was observed more frequently when the ER status (p = 0.023) or PR status (p = 0.010) of primary tumor was negative, while HER2 discordance seemed to be more frequent when the HER2 status of primary tumor was HER2-0 or HER2-low (p < 0.001). Patients with loss of HR-positivity (positive to negative) responded to neoadjuvant chemotherapy better compared to those with stable positive HR expression (50% vs. 11.1%, p = 0.0017). A significantly decrease in pCR rate was observed in patients with unstable HER2 status, but not in the HER2-0/HER2-low subgroup. Conclusion: Receptor discordance between primary tumor and synchronous axillary LNM appears to already exist before any anti-tumor therapy. This instability has limited clinical impact on the choice of neoadjuvant therapy at current stage, but further investigation is warranted with the incremental application of endocrine drugs and ADCs in neoadjuvant therapy.
- 8 June 2024
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 150 (6) , 1-11
Open AccessBiomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis
Purpose: The biomarker characteristics of breast cancer plays an important role in predicting treatment sensitivity. The aim of the present study was to compare immunohistochemical profiles (ER, PR, HER2, and Ki67) between the primary tumor and synchronous axillary lymph node metastasis and investigate the subsequent effects on neoadjuvant therapy response. Methods: A total of 358 patients with pathologically confirmed synchronous axillary lymph node metastasis at first diagnosis and treated by neoadjuvant therapy at Peking University First Hospital from January 1, 2013 to December 31, 2022 were included in this retrospective study. Clinicopathologic data, especially receptor status in primary and metastatic foci, was collected for each case. Results: Change of ER, PR, HER2, and Ki67 expression was observed in 5.9%, 8.7%, 12.6%, and 17.3% of patients, respectively. HR discordance was observed more frequently when the ER status (p = 0.023) or PR status (p = 0.010) of primary tumor was negative, while HER2 discordance seemed to be more frequent when the HER2 status of primary tumor was HER2-0 or HER2-low (p < 0.001). Patients with loss of HR-positivity (positive to negative) responded to neoadjuvant chemotherapy better compared to those with stable positive HR expression (50% vs. 11.1%, p = 0.0017). A significantly decrease in pCR rate was observed in patients with unstable HER2 status, but not in the HER2-0/HER2-low subgroup. Conclusion: Receptor discordance between primary tumor and synchronous axillary LNM appears to already exist before any anti-tumor therapy. This instability has limited clinical impact on the choice of neoadjuvant therapy at current stage, but further investigation is warranted with the incremental application of endocrine drugs and ADCs in neoadjuvant therapy.
- Open Access
- 12 March 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1360507
Integrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options. Although immune checkpoint inhibitors (ICIs) have been proven to improve outcomes in TNBC patients, the potential mechanisms and markers that determine the therapeutic response to ICIs remains uncertain. Revealing the relationship and interaction between cancer cells and tumor microenvironment (TME) could be helpful in predicting treatment efficacy and developing novel therapeutic agents. By analyzing single-cell RNA sequencing dataset, we comprehensively profiled cell types and subpopulations as well as identified their signatures in the TME of TNBC. We also proposed a method for quantitatively assessment of the TME immune profile and provided a framework for identifying cancer cell-intrinsic features associated with TME through integrated analysis. Using integrative analyses, RARRES1 was identified as a TME-associated gene, whose expression was positively correlated with prognosis and response to ICIs in TNBC. In conclusion, this study characterized the heterogeneity of cellular components in TME of TNBC patients, and brought new insights into the relationship between cancer cells and TME. In addition, RARRES1 was identified as a potential predictor of prognosis and response to ICIs in TNBC.
- 12 March 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1360507
Open AccessIntegrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options. Although immune checkpoint inhibitors (ICIs) have been proven to improve outcomes in TNBC patients, the potential mechanisms and markers that determine the therapeutic response to ICIs remains uncertain. Revealing the relationship and interaction between cancer cells and tumor microenvironment (TME) could be helpful in predicting treatment efficacy and developing novel therapeutic agents. By analyzing single-cell RNA sequencing dataset, we comprehensively profiled cell types and subpopulations as well as identified their signatures in the TME of TNBC. We also proposed a method for quantitatively assessment of the TME immune profile and provided a framework for identifying cancer cell-intrinsic features associated with TME through integrated analysis. Using integrative analyses, RARRES1 was identified as a TME-associated gene, whose expression was positively correlated with prognosis and response to ICIs in TNBC. In conclusion, this study characterized the heterogeneity of cellular components in TME of TNBC patients, and brought new insights into the relationship between cancer cells and TME. In addition, RARRES1 was identified as a potential predictor of prognosis and response to ICIs in TNBC.
An ultrasound‐based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation
Introduction: The staging and treatment of axillary nodes in breast cancer have become a focus of research. For breast cancer patients with fine‐needle aspiration—or core needle biopsy—confirmed positive nodes, axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) is still a standard treatment. However, some patients achieve an axillary pathologic complete response (pCR) after NAC. In this study, the authors sought to construct a model to predict axillary pCR in patients with positive axillary lymph nodes (cN+) breast cancer.Methods: Data from patients with pathologically proven cN+ breast cancer treated with NAC followed by ALND between January 2010 and April 2019 at the Peking University Cancer Hospital were reviewed. Axillary lymph node status was assessed using ultrasonography before and after NAC. The patient cohort was assigned to the construction and internal validation cohorts according to admission time. A nomogram was constructed based on the significant factors associated with axillary pCR. The predictive performance of the model was externally validated using data from Peking University First Hospital.Results: This study included 953 and 267 patients from Peking University Cancer Hospital and Peking University First Hospital, respectively. In the construction cohort, 39.7% (238 of 600) of patients achieved axillary pCR after NAC. The result of multivariate logistic regression analysis showed that tumor grade, clinical nodal response, NAC regimen, tumor pCR, lymphovascular invasion, and tumor biologic subtype were significant independent predictors of ypN0 (p < 0.05). The areas under the receiver operating characteristic curves for the construction, validation, and independent testing cohorts were 0.87 (95% confidence interval [CI], 0.84–0.90), 0.83 (95% CI, 0.79–0.87), and 0.84 (0.79–0.89), respectively.Conclusions: A nomogram was constructed to predict the pCR of axillary lymph nodes after NAC for breast cancer. Validation of both the internal and external cohorts achieved good predictive performance, indicating that the model has preliminary clinical application prospects.
An ultrasound‐based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation
Introduction: The staging and treatment of axillary nodes in breast cancer have become a focus of research. For breast cancer patients with fine‐needle aspiration—or core needle biopsy—confirmed positive nodes, axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) is still a standard treatment. However, some patients achieve an axillary pathologic complete response (pCR) after NAC. In this study, the authors sought to construct a model to predict axillary pCR in patients with positive axillary lymph nodes (cN+) breast cancer.Methods: Data from patients with pathologically proven cN+ breast cancer treated with NAC followed by ALND between January 2010 and April 2019 at the Peking University Cancer Hospital were reviewed. Axillary lymph node status was assessed using ultrasonography before and after NAC. The patient cohort was assigned to the construction and internal validation cohorts according to admission time. A nomogram was constructed based on the significant factors associated with axillary pCR. The predictive performance of the model was externally validated using data from Peking University First Hospital.Results: This study included 953 and 267 patients from Peking University Cancer Hospital and Peking University First Hospital, respectively. In the construction cohort, 39.7% (238 of 600) of patients achieved axillary pCR after NAC. The result of multivariate logistic regression analysis showed that tumor grade, clinical nodal response, NAC regimen, tumor pCR, lymphovascular invasion, and tumor biologic subtype were significant independent predictors of ypN0 (p < 0.05). The areas under the receiver operating characteristic curves for the construction, validation, and independent testing cohorts were 0.87 (95% confidence interval [CI], 0.84–0.90), 0.83 (95% CI, 0.79–0.87), and 0.84 (0.79–0.89), respectively.Conclusions: A nomogram was constructed to predict the pCR of axillary lymph nodes after NAC for breast cancer. Validation of both the internal and external cohorts achieved good predictive performance, indicating that the model has preliminary clinical application prospects.